Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 10/20 | 0.84 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.80 |
| ▸ | PRKCG | P05129 | 1/20 | 0.80 |
| ▸ | PRKCB | P05771 | 1/20 | 0.80 |
| ▸ | PRKCH | P24723 | 1/20 | 0.80 |
| ▸ | PRKCI | P41743 | 1/20 | 0.80 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.80 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.80 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.80 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.80 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.80 |
| ▸ | TOP1 | P11387 | 12/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rebeccamycin SCHEMBL14069957 | 1.00 | DYRK1A (1.00) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Rebeccamycin SCHEMBL24695 | 1.00 | DYRK1A (1.00) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Rebeccamycin SCHEMBL30194716 | 1.00 | DYRK1A (1.00) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Rebeccamycin SCHEMBL32690193 | 1.00 | DYRK1A (1.00) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| SCHEMBL10027492 | 0.89 | DYRK1A (0.81) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| SCHEMBL7165791 | 0.86 | DYRK1A (0.76) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Rebeccamycin SCHEMBL19100060 | 0.86 | DYRK1A (0.75) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Becatecarin SCHEMBL5953888 | 0.85 | PRKCA (0.78) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Becatecarin SCHEMBL5953787 | 0.85 | PRKCA (0.78) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Becatecarin SCHEMBL31237559 | 0.85 | PRKCA (0.78) | DYRK1APAX8PRKCAPRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166241-B2 | Combination Therapy III | TURUN YLIOPISTO (FI) | 2019-01-01 | — | — | US | disclosed |
| US-9724331-B2 | Use of maleimide derivatives for preventing and treating leukemia | CENTOGENE AG (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9476050-B2 | Combination therapy | TURUN YLIOPISTO (FI) | 2016-10-25 | — | — | US | disclosed |
| US-20150313882-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | CENTOGENE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150306070-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | CENTOGENE AG (DE) | 2015-10-29 | — | — | US | disclosed |
| US-20150209369-A1 | COMBINATION THERAPY III | TURUN YLIOPISTO (FI) | 2015-07-30 | — | — | US | disclosed |
| US-20140135377-A1 | COMBINATION THERAPY | TURUN YLIOPISTO (FI) | 2014-05-15 | — | — | US | disclosed |
| US-8288527-B2 | Oligo-aminosaccharide compound | THE UNIVERSITY OF TOKYO (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20110003980-A1 | Oligo-Aminosaccharide compound | THE UNIVERSITY OF TOKYO (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313882-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | MGMT, CBR3, IDH3A | DYRK1A 2468/4885PAX8 1525/4885PRKCA 4732/4885 |
| US-20110003980-A1 | Oligo-Aminosaccharide compound | DDOST, STT3A, STT3B | DYRK1A 1631/4885PAX8 2970/4885PRKCA 3409/4885 |
| US-20150306070-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | MCL1, NPM1, FLI1 | DYRK1A 2505/4885PAX8 1434/4885PRKCA 4688/4885 |
| US-20150209369-A1 | COMBINATION THERAPY III | HDAC4, HDAC3, HDAC5 | DYRK1A 3668/4885PAX8 3986/4885PRKCA 1625/4885 |
| US-10166241-B2 | Combination Therapy III | HDAC4, HDAC3, HDAC5 | DYRK1A 3668/4885PAX8 3986/4885PRKCA 1625/4885 |
| US-20140135377-A1 | COMBINATION THERAPY | MCL1, PTPMT1, MTMR1 | DYRK1A 3812/4885PAX8 4531/4885PRKCA 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.